BACKGROUND: Retroperitoneal lymph node dissection has been advocated for the management of post-chemotherapy (PC-RPLND) residual masses of non-seminomatous germ cell tumors of the testis (NSGCT). There remains some debate as to the clinical benefit and associated morbidity. Our objective was to report our experience with PC-RPLND in NSGCT. METHODS: We have reviewed the clinical, pathologic and surgical parameters associated with PC-RPLND in a single institution. Between 1994 and 2008, three surgeons operated 73 patients with residual masses after cisplatin-based chemotherapy for a metastatic testicular cancer. Patients needed to have normal postchemotherapy serum tumor markers, no prior surgical attempts to resect retroperitoneal masses and resectable retroperitoneal tumor mass at surgery to be included in this analysis RESULTS: Mean age was 30.4 years old. Fifty-three percent had mixed germ cell tumors. The mean size of retroperitoneal metastasis was 6.3 and 4.0 cm, before and post-chemotherapy, respectively. In 56% of patients, the surgeon was able to perform a nerve sparing procedure. The overall complication rate was 27.4% and no patient died due to surgical complications. The pathologic review showed presence of fibrosis/necrosis, teratoma and viable tumor (non-teratoma) in 27 (37.0%), 30 (41.1%) and 16 (21.9%) patients, respectively. The subgroups presenting fibrosis and large tumors were more likely to have a surgical complication and had less nerve sparing procedures. CONCLUSION: PC-RPLND is a relatively safe procedure. The presence of fibrosis and large residual masses are associated with surgical complications and non-nerve-sparing procedure.
BACKGROUND: Retroperitoneal lymph node dissection has been advocated for the management of post-chemotherapy (PC-RPLND) residual masses of non-seminomatous germ cell tumors of the testis (NSGCT). There remains some debate as to the clinical benefit and associated morbidity. Our objective was to report our experience with PC-RPLND in NSGCT. METHODS: We have reviewed the clinical, pathologic and surgical parameters associated with PC-RPLND in a single institution. Between 1994 and 2008, three surgeons operated 73 patients with residual masses after cisplatin-based chemotherapy for a metastatic testicular cancer. Patients needed to have normal postchemotherapy serum tumor markers, no prior surgical attempts to resect retroperitoneal masses and resectable retroperitoneal tumor mass at surgery to be included in this analysis RESULTS: Mean age was 30.4 years old. Fifty-three percent had mixed germ cell tumors. The mean size of retroperitoneal metastasis was 6.3 and 4.0 cm, before and post-chemotherapy, respectively. In 56% of patients, the surgeon was able to perform a nerve sparing procedure. The overall complication rate was 27.4% and no patient died due to surgical complications. The pathologic review showed presence of fibrosis/necrosis, teratoma and viable tumor (non-teratoma) in 27 (37.0%), 30 (41.1%) and 16 (21.9%) patients, respectively. The subgroups presenting fibrosis and large tumors were more likely to have a surgical complication and had less nerve sparing procedures. CONCLUSION: PC-RPLND is a relatively safe procedure. The presence of fibrosis and large residual masses are associated with surgical complications and non-nerve-sparing procedure.
Authors: William F Hendry; Andrew R Norman; David P Dearnaley; Cyril Fisher; Judy Nicholls; Robert A Huddart; Alan Horwich Journal: Cancer Date: 2002-03-15 Impact factor: 6.860
Authors: Stephen B Williams; David W McDermott; Winston Dock; Eamonn Bahnson; Alexander M Berry; Graeme S Steele; Jerome P Richie Journal: J Urol Date: 2009-03-14 Impact factor: 7.450
Authors: Jonas Busch; Ahmed Magheli; Natalia Leva; Stefan Hinz; Michelle Ferrari; Frank Friedersdorff; Tom Florian Fuller; Kurt Miller; Mark L Gonzalgo Journal: World J Urol Date: 2014-03-09 Impact factor: 4.226
Authors: Jonas Busch; Ahmed Magheli; Barbara Erber; Frank Friedersdorff; Ivan Hoffmann; Carsten Kempkensteffen; Steffen Weikert; Kurt Miller; Mark Schrader; Stefan Hinz Journal: BMC Urol Date: 2012-05-31 Impact factor: 2.264
Authors: Eduardo de Paula Miranda; Daniel Kanda Abe; Adriano João Nesrallah; Sabrina Thalita dos Reis; Alexandre Crippa; Miguel Srougi; Marcos Francisco Dall'Oglio Journal: World J Surg Oncol Date: 2012-09-28 Impact factor: 2.754
Authors: Christian Guido Ruf; Simon Krampe; Cord Matthies; Petra Anheuser; Tim Nestler; Jörg Simon; Hendrik Isbarn; Klaus Peter Dieckmann Journal: World J Surg Oncol Date: 2020-09-24 Impact factor: 2.754